Exelixis Inc (EXEL)
23.73
+0.44
(+1.89%)
USD |
NASDAQ |
Apr 24, 14:45
Exelixis SG&A Expense (Quarterly): 131.44M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 131.44M |
September 30, 2023 | 138.14M |
June 30, 2023 | 141.72M |
March 31, 2023 | 131.40M |
December 31, 2022 | 119.25M |
September 30, 2022 | 114.98M |
June 30, 2022 | 122.76M |
March 31, 2022 | 102.86M |
December 31, 2021 | 99.31M |
September 30, 2021 | 101.56M |
June 30, 2021 | 98.50M |
March 31, 2021 | 102.35M |
December 31, 2020 | 82.44M |
September 30, 2020 | 88.18M |
June 30, 2020 | 59.79M |
March 31, 2020 | 62.94M |
December 31, 2019 | 58.03M |
September 30, 2019 | 51.26M |
June 30, 2019 | 58.82M |
March 31, 2019 | 60.14M |
December 31, 2018 | 52.38M |
September 30, 2018 | 48.12M |
June 30, 2018 | 51.85M |
March 31, 2018 | 54.02M |
December 31, 2017 | 46.25M |
Date | Value |
---|---|
September 30, 2017 | 38.13M |
June 30, 2017 | 40.67M |
March 31, 2017 | 34.29M |
December 31, 2016 | 13.00M |
September 30, 2016 | 32.46M |
June 30, 2016 | 35.82M |
March 31, 2016 | 34.86M |
December 31, 2015 | 17.14M |
September 30, 2015 | 17.84M |
June 30, 2015 | 12.79M |
March 31, 2015 | 9.531M |
December 31, 2014 | 9.766M |
September 30, 2014 | 9.906M |
June 30, 2014 | 16.47M |
March 31, 2014 | 14.69M |
December 31, 2013 | 13.64M |
September 30, 2013 | 13.60M |
June 30, 2013 | 13.18M |
March 31, 2013 | 10.54M |
December 31, 2012 | 9.829M |
September 30, 2012 | 7.343M |
June 30, 2012 | 6.76M |
March 31, 2012 | 7.905M |
December 31, 2011 | 7.01M |
September 30, 2011 | 8.171M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
51.26M
Minimum
Sep 2019
141.72M
Maximum
Jun 2023
98.20M
Average
101.56M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Regeneron Pharmaceuticals Inc | 737.70M |
Bristol-Myers Squibb Co | 2.073B |
Johnson & Johnson | 5.257B |
Bio-Techne Corp | 115.67M |
Legend Biotech Corp | 62.38M |